Health economics + value
WHAT WE DO
We combine rigorous analysis with strategic insight to support market access, funding decisions, and health system engagement. Our approach includes:
- Early value and reimbursement strategy development to align evidence generation and product positioning with payer expectations.
- Payer and HTA landscape scanning to identify access pathways, evaluation criteria, and policy or jurisdictional considerations.
- Quantitative analysis of value, cost, and impact using cost-effectiveness, budget impact, and willingness-to-pay modelling.
- Stakeholder engagement to validate assumptions and contextualise findings, including clinicians, payers, and consumer representatives.
- Description of value through structured submissions, briefing packs, and tailored messaging for policy and funding audiences.
- Development of tailored burden of disease and economic models.
TAILORED SOLUTIONS
We deliver a range of targeted outputs that support pricing, access, and funding decisions — tailored to your product’s stage, market context, and payer priorities. What this looks like:
- Payer landscape assessments to map funding pathways, decision-makers, and HTA considerations.
- Willingness-to-pay analysis to assess perceived value and inform pricing and positioning.
- Feasibility studies to evaluate the viability, risks and/or operational requirements of proposed clinical, commercial or strategic initiatives.
- Impact assessments to quantify clinical, economic, and system-wide benefits.
- Pricing negotiation support to identify options and secure optimal pricing and reimbursement terms for a product.
- HTA submission and reimbursement strategy to guide engagement, evidence planning, and submission sequencing.
- Economic models tailored to your needs.
Reports:
Policy research and analysis, Public Health
Fighting Superbugs: Ensuring Australia is ready to combat the rise of drug resistant infections
Evohealth Report Fighting Superbugs: Ensuring Australia is ready to…
Life Sciences, Policy research and analysis
Cell and gene therapies: Rising to the challenge Scorecard 2023
Scorecard 2023 Measuring Australia’s progress towards timely and…
Evaluation and economics, Policy research and analysis, Public Health
Time to Act: protecting our children from RSV
Evohealth Report Time to Act: protecting our children from RSVRespiratory..
Policy research and analysis, Public Health
Preparing Australia: Designing an Australian Centre for Disease Control (CDC)
For many Australians, the COVID-19 pandemic has been their defining…
Evaluation and economics, Policy research and analysis, Primary Care, Public Health
Cell and gene therapies: Rising to the challenge Scorecard 2023
Evohealth White Paper The burden of cancer in AustraliaIn Australia,…
Evaluation and economics, Policy research and analysis, Public Health
ASCVD in Taiwan: A public health priority
Evohealth White Paper ASCVD in Taiwan: A public health…
Life Sciences, Policy research and analysis
Cell and gene therapies: Rising to the challenge
Evohealth White Paper Cell and gene therapies: Rising to the…
Evaluation and economics, Policy research and analysis, Primary Care
Australia’s Cholesterol Heartache
A simple roadmap for urgent action on cholesterol managementAustralia has…
